Eli Lilly – Merida Biosciences

MN-80042

Eli Lilly and Company (Eli Lilly) proposes to acquire 100% of the issued shares in Merida Biosciences, Inc. (Merida Biosciences) (the Acquisition). Eli Lilly is a US-based pharmaceutical company which discovers, develops, manufactures and markets human pharmaceutical products for various therapeutic areas, including diabetes, oncology, immunology and neuroscience. Eli Lilly is headquartered in Indianapolis, the US and is publicly listed on the New York Stock Exchange. Merida Biosciences is a clinical-stage biotechnology company focused on developing treatments for certain autoimmune and allergic conditions. It was founded in 2022 and is headquartered in Massachusetts, the US. Merida Biosciences' is developing the following treatments: * MER511, a clinical-stage (Phase 1) thyroid-stimulating hormone receptor autoantibody degrader for the treatment of Graves' disease and thyroid eye disease. * MER769, a therapeutic antibody designed to neutralise and eliminate immunoglobin E (IgE) antibodies for the treatment of IgE-mediated allergic diseases. * MER683, which degrades autoantibodies for the treatment of primary membranous nephropathy, a chronic inflammatory kidney disease.